Since 2006, Ceva invested over $73 million to increase vaccine production capacity in our Lenexa, Kan. location. By 2026, we plan to invest an additional $40 million dollars in these facilities.
Since acquiring Biomune in 2005, Ceva has added over 200,000 square feet of production space for poultry and swine vaccines and over 100,000 sq. feet of additional warehouse space in the Kansas City region to support the biologics business.
Besides building a business domestically, vaccines produced in Lenexa are distributed to over 70 countries worldwide.